ClinicalTrials.gg

Program

DM5167

A development code.

Its studies are mostly in Breast Neoplasms, led by DIGMBIO.

Furthest: phase 1, since Jul 21, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
DIGMBIO11 open or runningphase 1since Jul 21, 2025Jul 21, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2025First study: phase 1 study in Advanced Breast CancerFirst studyNCT07101601 · 58 planned · South Korea

TargetBeta

PARP1 →read by rule
“DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme.”study text, by rule · the study

Other programs on PARP1

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
saruparibruleAstraZenecaphase 314
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24
palacaparibAstraZenecaphase 23
PARP1 Inhibitor HS-10502ruleHansoh Pharmaceutical Groupphase 12
HSK46256ruleHaisco Pharmaceutical Groupphase 11
TQB3122Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07101601Advanced Breast Cancer · South Korea1RecruitingOct 30, 202658

How it is read

Names in the registry

  • “DM5167”, 1 entry

Codes read as this program: DM5167.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.